Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKRO Akero Therapeutics

交易中 04-29 09:46:16 EDT

19.78

+0.04

+0.20%

最高19.81	最低19.55	成交量2.02万
今开19.64	昨收19.74	日振幅1.29%
总市值13.68亿	流通市值11.19亿	总股本6,915万
成交额39.63万	换手率0.04%	流通股本5,659万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKRO","market":"US","secType":"STK","nameCN":"Akero Therapeutics","latestPrice":19.78,"timestamp":1714398303048,"preClose":19.74,"halted":0,"volume":20153,"delay":0,"floatShares":56591206,"shares":69151007,"eps":-2.886899,"marketStatus":"交易中","marketStatusCode":2,"change":0.04,"latestTime":"04-29 09:46:16 EDT","open":19.64,"high":19.805,"low":19.55,"amount":396339.01480600005,"amplitude":0.012918,"askPrice":19.92,"askSize":20,"bidPrice":19.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.886899,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1714420800000},"adr":0,"listingDate":1561003200000,"adjPreClose":19.74,"postHourTrading":{"tag":"盘后","latestPrice":19.42,"preClose":19.74,"latestTime":"19:13 EDT","volume":250,"amount":4892.2,"timestamp":1714173221761},"volumeRatio":0.664927},"requestUrl":"/m/hq/s/AKRO/tweets","defaultTab":"tweets","newsList":[{"id":"2430828675","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大跌5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430828675","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430828675?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:40","pubTimestamp":1714052402,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时40分，Akero Therapeutics, Inc.股票出现波动，股价急速下挫5.75%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.31%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。该信息摘要如下：B of A Securities：重申Akero Therapeutics中性评级, 目标价30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252140027923762c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252140027923762c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429418459","title":"B of A Securities：重申Akero Therapeutics(AKRO.US)中性评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429418459","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429418459?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:35","pubTimestamp":1713782112,"startTime":"0","endTime":"0","summary":"B of A Securities：重申Akero Therapeutics(AKRO.US)中性评级, 目标价30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221835168b45cc0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221835168b45cc0a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421778342","title":"Akero Therapeutics, Inc.盘中异动 快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421778342","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421778342?lang=zh_cn&edition=full","pubTime":"2024-03-21 00:27","pubTimestamp":1710952051,"startTime":"0","endTime":"0","summary":"北京时间2024年03月21日00时27分，Akero Therapeutics, Inc.股票出现波动，股价大幅下挫5.04%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.90%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403210027327a4dfdad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403210027327a4dfdad&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH，竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":"    路透社3月14日 - Madrigal Pharmaceuticals公司的  药物成为第一个获得监管部门批准的 ，用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝，因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前，该公司在开发这种疾病的治疗方法方面取得了有限的成功，这种疾病与肥胖密切相关，而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419009776","title":"Akero Therapeutics, Inc.盘中异动 股价大跌5.11%报26.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419009776","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419009776?lang=zh_cn&edition=full","pubTime":"2024-03-14 21:53","pubTimestamp":1710424394,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日21时53分，Akero Therapeutics, Inc.股票出现异动，股价快速下挫5.11%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.26%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314215315791a7ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314215315791a7ca4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417200459","title":"美国研究综述-树皮、Fleetcor Technologies、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2417200459","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417200459?lang=zh_cn&edition=full","pubTime":"2024-03-05 14:57","pubTimestamp":1709621845,"startTime":"0","endTime":"0","summary":"    路透社3月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Bark、Fleetcor Technologies 和特斯拉。要闻             * Bark Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"；将交易价从1.54美元上调至1.9美元。* Fleetcor Technologies Inc   ：贝尔德将其评级上调至 \"跑赢大盘\"。* 特斯拉  ：加拿大皇家银行将目标价从297美元上调至298美元 以下是路透社周二报道的美国公司研究报告摘要。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company   ：摩根大通将其股票评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持  * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元  * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元  * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416111226","title":"Akero脂肪性肝炎药物试验结果积极，盘前大涨20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416111226","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2416111226?lang=zh_cn&edition=full","pubTime":"2024-03-04 20:20","pubTimestamp":1709554847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Akero Therapeutics称，该公司的一项2b期研究在第96周取得了积极的初步结果，该研究评估了其主要候选产品Efruxifermin在肝硬化前代谢功能障碍相关性脂肪性肝炎、纤维化2期或3期患者中的疗效和安全性。消息发布后，Akero应声大涨，一度暴涨97.81%，截至发稿，该公司盘前涨21.54%，报33.8美元。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1081199.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2416116440","title":"BUZZ-脂肪肝药物在试验中减少瘢痕形成，Akero Therapeutics公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2416116440","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416116440?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:25","pubTimestamp":1709551501,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月4日 - ** 药物开发商Akero Therapeutics  股价盘前上涨89%至52.55美元** 该公司表示， (link)，其治疗MASH（一种脂肪肝）的主要实验药物在96周后减少了患者器官的瘢痕，达到了中期研究的主要目标** MASH即代谢功能障碍相关性脂肪性肝炎，约有5%的美国人患有这种疾病。** 截至上次收盘，股价在过去 12 个月中下跌了 41.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416116902","title":"更新版 1-Akero公司的主导药物有助于减轻脂肪肝患者的瘢痕形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2416116902","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416116902?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:22","pubTimestamp":1709551329,"startTime":"0","endTime":"0","summary":"     路透社3月4日 - Akero Therapeutics   周一表示，其治疗一种脂肪肝的主要实验药物在96周后有助于减少瘢痕，达到了中期研究的主要目标。96周时瘢痕的减少 率明显高于24周时的减少 率，这表明该药物能持续改善病情。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416115097","title":"Akero公司的主导药物有助于改善脂肪肝患者的瘢痕形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2416115097","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416115097?lang=zh_cn&edition=full","pubTime":"2024-03-04 19:09","pubTimestamp":1709550564,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月4日 - Akero Therapeutics   周一表示，其治疗一种脂肪肝的主要实验药物在96周后有助于改善患者器官的瘢痕，达到了一项中期研究的主要目标。受此消息影响，该公司股价飙升 91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415547226","title":"Akero Therapeutics, Inc.盘中异动 大幅拉升5.64%报28.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415547226","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415547226?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:30","pubTimestamp":1709217053,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时30分，Akero Therapeutics, Inc.股票出现波动，股价大幅上涨5.64%。截至发稿，该股报28.77美元/股，成交量1.4626万股，换手率0.03%，振幅0.18%。Akero Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Akero Therapeutics, Inc.公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402292230547a482f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402292230547a482f48&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413409762","title":"Akero Therapeutics Inc盘中异动 大幅拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413409762","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413409762?lang=zh_cn&edition=full","pubTime":"2024-02-23 22:44","pubTimestamp":1708699487,"startTime":"0","endTime":"0","summary":"北京时间2024年02月23日22时44分，Akero Therapeutics Inc股票出现波动，股价快速上涨5.04%。Akero Therapeutics Inc股票所在的生物技术行业中，整体涨幅为0.82%。Akero Therapeutics Inc公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402232244477a46250f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402232244477a46250f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411735031","title":"Akero Therapeutics Inc盘中异动 大幅跳水5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411735031","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411735031?lang=zh_cn&edition=full","pubTime":"2024-02-13 22:31","pubTimestamp":1707834713,"startTime":"0","endTime":"0","summary":"北京时间2024年02月13日22时31分，Akero Therapeutics Inc股票出现异动，股价大幅下跌5.99%。Akero Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.66%。其相关个股中，Biodexa Pharmaceuticals Plc、Bioxcel Therapeutics Inc、Adial Pharmaceuticals Inc涨幅较大，Biodexa Pharmaceuticals Plc、Adial Pharmaceuticals Inc、Kintara Therapeutics Inc较为活跃，换手率分别为296.56%、81.54%、30.14%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Biovie Inc、Rhythm Pharmaceuticals Inc，振幅分别为12.41%、12.28%、10.90%。Akero Therapeutics Inc公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的变革性治疗，具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021322315479113baf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021322315479113baf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409403983","title":"BUZZ-礼来公司的药物在试验中显示出前景，NASH 药物开发商纷纷倒下","url":"https://stock-news.laohu8.com/highlight/detail?id=2409403983","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409403983?lang=zh_cn&edition=full","pubTime":"2024-02-06 21:38","pubTimestamp":1707226735,"startTime":"0","endTime":"0","summary":"    2月6日 - ** 在礼来公司的  减肥药达到了脂肪肝患者中期试验的主要目标后，开发治疗NASH药物的公司股价在上市前下跌 ** 礼来公司周二在 ，称替泽帕肽帮助多达73.9%的患者实现了 \"不发病\"，52周时肝脏瘢痕没有恶化。** 89bio Inc   等其他NASH药物开发商的股价下跌10.7%，NeuroBo Pharmaceuticals   下跌3.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akerotx.com","stockEarnings":[{"period":"1week","weight":-0.0491},{"period":"1month","weight":-0.1926},{"period":"3month","weight":-0.1076},{"period":"6month","weight":0.7346},{"period":"1year","weight":-0.5476},{"period":"ytd","weight":-0.1546}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akero Therapeutics, Inc.于2017年1月根据特拉华州法律注册成立。他们是一家临床阶段的生物技术公司，致力于开发和商业化针对严重代谢疾病的转化疗法，以及高度未满足的医疗需求。他们最初关注的是非酒精性脂肪性肝炎，或NASH，一种没有任何批准疗法的疾病。NASH是一种非酒精性脂肪性肝病（NAFLD）的严重形式，其特征在于肝脏中的炎症和纤维化，其可发展为肝硬化，肝衰竭，癌症和死亡。NASH是肝移植的主要原因。他们的主要产品候选药物AKR-001，他们正在开发作为NASH患者的潜在治疗药物，是成纤维细胞生长因子21或FGF21的类似物。FGF21是一种内源性表达的激素，可调节全身脂质，碳水化合物和蛋白质的代谢。FGF21在保护许多类型的细胞免受各种形式的压力方面也起着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.018028},{"month":2,"riseRate":0.6,"avgChangeRate":0.019077},{"month":3,"riseRate":0,"avgChangeRate":-0.098995},{"month":4,"riseRate":0.4,"avgChangeRate":-0.057188},{"month":5,"riseRate":0.25,"avgChangeRate":-0.020964},{"month":6,"riseRate":0.5,"avgChangeRate":0.01727},{"month":7,"riseRate":0.6,"avgChangeRate":0.109984},{"month":8,"riseRate":0.8,"avgChangeRate":0.094367},{"month":9,"riseRate":0.4,"avgChangeRate":0.324789},{"month":10,"riseRate":0.4,"avgChangeRate":-0.135837},{"month":11,"riseRate":0.6,"avgChangeRate":0.085265},{"month":12,"riseRate":0.6,"avgChangeRate":0.118372}],"exchange":"NASDAQ","name":"Akero Therapeutics","nameEN":"Akero Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akero Therapeutics,AKRO,Akero Therapeutics股票,Akero Therapeutics股票老虎,Akero Therapeutics股票老虎国际,Akero Therapeutics行情,Akero Therapeutics股票行情,Akero Therapeutics股价,Akero Therapeutics股市,Akero Therapeutics股票价格,Akero Therapeutics股票交易,Akero Therapeutics股票购买,Akero Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}